Israeli-American startup Immunai has secured an $18 million partnership with AstraZeneca to improve the effectiveness of cancer drug trials. Immunai has developed an AI platform to map and decode the human immune system, using machine learning and big data computation to accelerate drug development. AstraZeneca will use Immunai's AI model and machine learning capabilities for clinical decision-making, dose selection, and biomarker identification. Immunai has raised close to $270 million in funding and has partnerships with top pharmaceutical companies and academic institutions. Israeli startups have been increasingly utilized by pharma companies for AI technologies in drug discovery and development.